01 September 2009
Katie McQue
katie.mcque@informa.com
The US FDA has accepted Johnson & Johnson's reply to a complete response letter for its antibiotic ceftobiprole, issued last November.
Ceftobiprole was filed for the treatment of complicated skin and skin structure infections in 2007. J&J licensed the broad-spectrum anti-MRSA cephalosporin...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US Capitol Capsule: Supreme Court takes another stab at refining US patent law
- Zerit, Tygacil and Brinavess in latest CHMP restrictions
- US Capitol Capsule: PhRMA hopes Part D savings will be muscle against 'Super Congress' cuts
- Mirabegron approved in first market as Gardasil and Rotarix also get formal Japanese nod
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
